… In the phase 3 portion of an adaptive trial, we randomly assigned outpatients with Covid-19
and risk factors for severe disease to receive various doses of intravenous REGEN-COV or …

… demonstrated efficacy in symptomatic outpatients, where it rapidly reduced viral load and …
of REGEN-COV. Here, we report the primary analysis results of the phase 3 portion of this trial. …

… demonstrates potent in vitro neutralizing activity against SARS-CoV-2 VOCs … results (N =
275) from the phase 1/2/3 trial assessing the efficacy and safety of REGEN-COV in outpatients …

… outpatients with mild-to-moderate COVID-19, and for post-exposure prophylaxis in the United
States and other jurisdictions [5-7]. In outpatients … associated with SARS-CoV-2 infection in …

… 2 (SARS-CoV-2), physicians and scientists have searched for an outpatient treatment option
… antibodies that targets the spike protein of SARS-CoV-2, was recently given emergency use …

… This current study evaluates the virologic efficacy and the safety of a range of IV and SC
doses of REGEN-COV in outpatients with asymptomatic SARS-CoV-2 infection, or symptomatic …

… outpatients with mild-to-moderate COVID-19, no patient experienced symptom progression
or required hospitalization following treatment with REGEN-COV [24]… with REGEN-COV led to …

… outcomes in pregnant patients who received REGEN-COV and compare these outcomes with
… who tested positive for SARS-CoV-2 but did not receive REGEN-COV. This study aimed to …

… In outpatients with Covid-19, the use of REGEN-COV has been shown to reduce the incidence
of hospitalization or death from any cause by approximately 70%, rapidly reduce the viral …

… a trial in symptomatic outpatients at high risk for … REGEN-COV for participants who did
become symptomatic in this study (6 days) was similar to that observed in symptomatic outpatients …